This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
rifampicin
Rifampicin
Semisynthetic rifamycin antibiotic and potent CYP3A4/P-gp inducer. Bactericidal against dividing and dormant mycobacteria via rpoB RNA polymerase inhibition. Backbone of first-line TB (HRZE); also used in leprosy, meningococcal prophylaxis, and MRSA biofilm.
Entry Metadata
| Field | Value |
|---|---|
| ID | rifampicin |
| Name | Rifampicin |
| Status | draft |
| Last reviewed | 2026-06-04 |
| Stream | 01-modern |
| Drug class | rifamycin antibiotic |
Cross-Atlas Connections
Sources
- Sensi P, Margalith P, Timbal MT. Rifomycin, a new antibiotic — preliminary report. Farmaco Ed Sci. 1959;14:146-7. (Original rifomycin discovery)
- World Health Organization. Consolidated Guidelines on Tuberculosis, Module 4: Treatment — Drug-Susceptible Tuberculosis Treatment. WHO; 2022.
- Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle. 1985;66(3):219-25. · PubMed 3884428